[EN] NOVEL COMPOUNDS AND COMPOSITIONS USED AS ANTICANCER AGENTS<br/>[FR] NOUVEAUX COMPOSES ET COMPOSITIONS UTILISES COMME ANTICANCEREUX
申请人:UNIV PARIS DIDEROT PARIS 7
公开号:WO2013114040A1
公开(公告)日:2013-08-08
La présente invention concerne de nouveaux composés organiques, leur procédé de synthèse, et leurs utilisations notamment dans le domaine du traitement du cancer. En particulier, la présente invention concerne de nouveaux composés anticancéreux, notamment des composés capables d'inhiber l'enzyme mTOR (marmalian target of rapamycine)de manière efficace. L'invention concerne également des compositions pharmaceutiques ou non pharmaceutiques comportant lesdits composés.
Benzofuran derivatives as a novel class of inhibitors of mTOR signaling
High-throughput screening (HTS) hit 1 was previously identified as an inhibitor of the Akt/mTOR (Akt/mammalian target of rapamycin) signaling, which is a major target in oncology. The cytotoxicity of 1 was determined on a panel of human cancer cells lines with an IC50 comprised between 30 and 140 mu M. Subsequent structure activity relationship (SAR) studies led us to the identification of compounds that displayed an enhanced cytotoxicity. We demonstrated also that these molecules directly bind to mTOR complex 1 (mTORC1) and inhibit its kinase activity. (C) 2013 Elsevier Masson SAS. All rights reserved.
Benzofuran derivatives as anticancer inhibitors of mTOR signaling
A series of 32 derivatives and isosteres of the mTORinhibitor 2 were synthesized and compared for their cytotoxicity in radioresistant SQ20B cancer cell line. Several of these compounds, in particular 30b, were significantly more cytotoxic than 2. Importantly, 30b was shown to block both mTORC1 and Akt signaling, suggesting insensitivity to the resistance associated to Akt overactivation observed